Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00474786




Registration number
NCT00474786
Ethics application status
Date submitted
15/05/2007
Date registered
17/05/2007
Date last updated
21/11/2013

Titles & IDs
Public title
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Scientific title
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
Secondary ID [1] 0 0
B1771003
Secondary ID [2] 0 0
3066K1-404
Universal Trial Number (UTN)
Trial acronym
INTORSECT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Renal Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sorafenib
Treatment: Drugs - temsirolimus (Torisel)

Experimental: 1 -

Experimental: 2 -


Treatment: Drugs: Sorafenib
Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).

Treatment: Drugs: temsirolimus (Torisel)
Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS)
Timepoint [1] 0 0
Baseline up to 24 Months
Secondary outcome [1] 0 0
Progression Free Survival (PFS) by Investigator Assessment
Timepoint [1] 0 0
Baseline up to 24 Months
Secondary outcome [2] 0 0
Percentage of Participants With Tumor Response
Timepoint [2] 0 0
Baseline up to 24 Months
Secondary outcome [3] 0 0
Overall Survival (OS)
Timepoint [3] 0 0
Baseline to date of death from any cause (up to 24 months)
Secondary outcome [4] 0 0
Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment
Timepoint [4] 0 0
Weeks 12, 24, and 36
Secondary outcome [5] 0 0
Duration of Response (DR)
Timepoint [5] 0 0
Baseline up to 24 Months

Eligibility
Key inclusion criteria
* Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy status) with well-documented Radiological PD by RECIST criteria or clinical PD as judged by the investigator while receiving first-line sunitinib therapy. Subjects must have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).
* At time of randomization, at least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery.
* At time of randomization, there must be at least 1 measurable lesion per RECIST. Lesions that have been previously irradiated or embolized cannot be selected as target lesions.

* More criteria apply
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Metastatic CNS from RCC.
* Subjects who discontinued Sutent therapy due specifically to intolerance.
* Prior systemic therapy for mRCC other than sunitinib.
* Active ketonuria, secondary to poorly controlled diabetes mellitus

* More criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2013
Sample size
Target
Accrual to date
Final
512
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Kogarah
Recruitment hospital [2] 0 0
Pfizer Investigational Site - St Leonards
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Westmead
Recruitment hospital [4] 0 0
Pfizer Investigational Site - South Brisbane
Recruitment hospital [5] 0 0
Pfizer Investigational Site - Adelaide
Recruitment hospital [6] 0 0
Pfizer Investigational Site - Elizabeth Vale
Recruitment hospital [7] 0 0
Pfizer Investigational Site - Woodville South
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [7] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Mississippi
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Utah
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
Argentina
State/province [14] 0 0
Santa Fé
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Nueva Cordoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Tucuman
Country [18] 0 0
Austria
State/province [18] 0 0
Salzburg
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Nova Scotia
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
Chile
State/province [25] 0 0
Santiago
Country [26] 0 0
China
State/province [26] 0 0
Hong Kong
Country [27] 0 0
Denmark
State/province [27] 0 0
Aarhus C
Country [28] 0 0
Denmark
State/province [28] 0 0
Herlev
Country [29] 0 0
Finland
State/province [29] 0 0
Tampere
Country [30] 0 0
Finland
State/province [30] 0 0
Turku
Country [31] 0 0
France
State/province [31] 0 0
Cedex 5
Country [32] 0 0
France
State/province [32] 0 0
Angers
Country [33] 0 0
France
State/province [33] 0 0
Besancon
Country [34] 0 0
France
State/province [34] 0 0
Bordeaux
Country [35] 0 0
France
State/province [35] 0 0
Caen Cedex 05
Country [36] 0 0
France
State/province [36] 0 0
Clermont-Ferrand Cedex 1
Country [37] 0 0
France
State/province [37] 0 0
Dijon
Country [38] 0 0
France
State/province [38] 0 0
Lille
Country [39] 0 0
France
State/province [39] 0 0
Lyon Cedex 08
Country [40] 0 0
France
State/province [40] 0 0
Marseille Cedex 9
Country [41] 0 0
France
State/province [41] 0 0
Paris Cedex 15
Country [42] 0 0
France
State/province [42] 0 0
Poitiers Cedex
Country [43] 0 0
France
State/province [43] 0 0
Saint Herlain/Nantes Cedex
Country [44] 0 0
France
State/province [44] 0 0
Strasbourg
Country [45] 0 0
France
State/province [45] 0 0
Vandoeuvre Les Nancy
Country [46] 0 0
France
State/province [46] 0 0
Villejuif Cedex
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Dresden
Country [49] 0 0
Germany
State/province [49] 0 0
Heidelberg
Country [50] 0 0
Germany
State/province [50] 0 0
Kassel
Country [51] 0 0
Germany
State/province [51] 0 0
Luebeck
Country [52] 0 0
Germany
State/province [52] 0 0
Muenchen
Country [53] 0 0
Germany
State/province [53] 0 0
Neuss
Country [54] 0 0
Germany
State/province [54] 0 0
Ulm
Country [55] 0 0
Hungary
State/province [55] 0 0
Budapest
Country [56] 0 0
Italy
State/province [56] 0 0
Chieti
Country [57] 0 0
Italy
State/province [57] 0 0
Firenze
Country [58] 0 0
Italy
State/province [58] 0 0
Napoli
Country [59] 0 0
Italy
State/province [59] 0 0
Pavia
Country [60] 0 0
Italy
State/province [60] 0 0
Roma
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Seoul
Country [62] 0 0
Netherlands
State/province [62] 0 0
Dordrecht
Country [63] 0 0
Netherlands
State/province [63] 0 0
Leeuwarden
Country [64] 0 0
Netherlands
State/province [64] 0 0
Zwolle
Country [65] 0 0
Singapore
State/province [65] 0 0
Singapore
Country [66] 0 0
Spain
State/province [66] 0 0
Asturias
Country [67] 0 0
Spain
State/province [67] 0 0
Barcelona
Country [68] 0 0
Spain
State/province [68] 0 0
Madrid
Country [69] 0 0
Spain
State/province [69] 0 0
Sevilla
Country [70] 0 0
Spain
State/province [70] 0 0
Valencia
Country [71] 0 0
Sweden
State/province [71] 0 0
Göteborg
Country [72] 0 0
Sweden
State/province [72] 0 0
Lund
Country [73] 0 0
Sweden
State/province [73] 0 0
Malmo
Country [74] 0 0
Switzerland
State/province [74] 0 0
Basel
Country [75] 0 0
Switzerland
State/province [75] 0 0
BS
Country [76] 0 0
Switzerland
State/province [76] 0 0
GE
Country [77] 0 0
Switzerland
State/province [77] 0 0
Bruderholz
Country [78] 0 0
Switzerland
State/province [78] 0 0
Luzern
Country [79] 0 0
Switzerland
State/province [79] 0 0
Rheinstrasse 26
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Birmingham
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Cambridgeshire
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Manchester
Country [83] 0 0
United Kingdom
State/province [83] 0 0
London
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Newcastle upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID). These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months. Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.
Trial website
https://clinicaltrials.gov/study/NCT00474786
Trial related presentations / publications
de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00474786